Background. High antenatal human immunodeficiency virus (HIV) seroprevalence rates (∼30%) with low perinatal HIV transmission rates (2.5%), due to HIV prevention of mother-to-child transmission program improvements in South Africa, has resulted in increasing numbers of HIV-exposed but uninfected (HEU) children. We aimed to describe the epidemiology of invasive pneumococcal disease (IPD) in HEU infants.
Programs for prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) have expanded over the last decade in many countries. South Africa reported a decrease in mother-to-child HIV transmission rates from 12% in 2007 to 2.7% in 2011 [1] and 2.5% during 2012-2013 [2] , despite a relatively constant prevalence of HIV in pregnant women of approximately 30%. This has resulted in an increasing number of HIV-exposed but uninfected (HEU) infants, especially in countries with elevated HIV prevalence such as South Africa.
All-cause hospitalization rates and complicated hospital admissions are more frequent in HEU than in HIV-unexposed and uninfected (HUU) infants [3, 4] . Some infectious diseases, including respiratory tract infections [5] , are more common and often more severe among HEU than HUU children. Compared with HIV-infected children, 1 study reported similar rates of pneumonia and bacterial meningitis in HEU children, but higher rates of gastroenteritis and sepsis [6] .
Some studies report higher mortality rates in HEU than HUU infants [7, 8] whereas others show no difference [9, 10] . In contrast, studies consistently report higher mortality rates in HIV-infected vs HEU or HUU infants [7] . Risk factors for mortality in HEU children include advanced maternal HIV disease [11, 12] , malnutrition [8] , severe pneumonia, and bacterial meningitis [6] . Mortality among HEU children peaks in younger infants (3-6 months), with death being predominantly associated with lower respiratory tract infections [8] . Within the general population, pneumococcus is estimated to cause 30%-40% of childhood community-acquired pneumonia cases [13] There are no published data evaluating or quantifying the risk of hospitalization or mortality associated with invasive pneumococcal disease (IPD) among HEU children. We aimed to describe the epidemiology of IPD from 2009 to 2013 in South African HEU infants <1 year of age, compared to the epidemiology of IPD in similarly aged HUU and HIV-infected infants.
METHODS

Study Design and Setting
Detailed methods are available in the Supplementary Appendix. Children hospitalized from 2009 through 2013 with laboratoryconfirmed IPD were prospectively identified by a national, laboratory-based, active surveillance program for Streptococcus pneumoniae. More than 200 routine hospital-based diagnostic laboratories (enhanced and nonenhanced hospital sites) systematically report IPD cases of all ages to the surveillance program. For the subset of cases occurring at 25 enhanced sentinel hospital sites, located in all 9 provinces, dedicated study surveillance officers collect additional clinical and demographic information.
Study Population
We included all infants <1 year of age with IPD from 2009 through 2013. For incidence calculations, infants from enhanced and nonenhanced sites were included. For analyses of factors associated with HIV exposure/infection status and mortality, only infants from enhanced sites with known HIV exposure status and in-hospital outcome were included.
Case Definitions
IPD cases were defined as S. pneumoniae identified from normally sterile site (eg, cerebrospinal fluid [CSF], blood, joint fluid, pleural fluid) specimens at participating sites. HUU infants were defined as infants with documented negative maternal HIV status at birth or time of illness, with or without a negative HIV enzyme-linked immunosorbent assay (ELISA) or polymerase chain reaction (PCR) result for the infant. HEU infants were defined as infants who had a negative HIV PCR result with known positive maternal HIV status (verbal or documented positive result) or infants with a positive HIV ELISA result and negative HIV PCR result. HEU infants who had symptoms suggestive of HIV at the current admission were retested. HIV-infected infants were defined as infants with a positive HIV PCR result before or at time of illness.
Incidence
We calculated annual incidence of pneumococcal disease from 2009 through 2013 for infants <1 year of age, by HIV infection/ exposure status, by dividing the number of laboratoryconfirmed IPD cases reported each year in each category (HEU, HUU, and HIV) by the midyear population estimates for each group. Population denominators were obtained from the THEMBISA model [14] . Due to significant decreasing trends in IPD incidence rates (IRs) from 2009 through 2013, resulting from progressive pneumococcal conjugate vaccine (PCV) introduction and HIV-related interventions [15] , we only presented data from 2 time points, prevaccine (2009) and postvaccine (2013) introduction.
As HIV infection/exposure status information was only available for cases identified at enhanced sites, we assumed a similar prevalence of HIV infection and exposure among cases with unknown (from nonenhanced sites) status as that found at enhanced sites. We calculated relative risk of IPD hospitalization comparing HEU children with HUU and HIV-infected children. Confidence intervals were calculated using Poisson distribution for incidence rates IRs and incidence rate ratios (IRRs).
Factors Associated With HIV Exposure Status and Death
We included infants <1 years of age with IPD from enhanced sites only, from 2009 through 2013, and developed 2 multivariable models to identify factors associated with outcome variables: (1) HIV infection/exposure status and (2) mortality.
Multinomial regression was used for comparison of factors associated with HIV infection/exposure. Multinomial regression allows modeling of outcome variables with >2 categories and relates the probability of being in category j to the probability of being in a baseline category. A complete set of coefficients are estimated for each of the j levels being compared with the baseline, and the effect of each predictor in the model is measured as relative risk ratio (RRR). HEU cases were used as the referent group and compared with HUU and HIV-infected infants so that all described differences would be related to exposed children. The model to assess factors associated with mortality used logistic regression and was presented stratified by age (<6 months and 6 to <12 months) as there was significant interaction between age and HIV infection/exposure status. Statistical analysis was implemented using Stata software, version 12 (StataCorp, College Station, Texas).
Ethics
Ethics approval was obtained for Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA) surveillance (M081117) from the Human Research Ethics Committee (Medical), University of the Witwatersrand, Johannesburg, South Africa, and other local hospital or provincial ethics committees, as required.
RESULTS
We identified 2099 IPD cases in infants <1 year of age from 2009 through 2013 from all sites ( Figure 1 (12/40) for HEU infants (P < .001); 72% (72/100) and 23% (15/64) for HUU infants (P < .001); and 85% (75/88) and 35% (7/20) (P < .001), for HIV-infected infants, respectively.
Incidence Rates
In 2009 (Table 1) , IPD incidence in the <1-year age group was higher in HIV-infected compared with HUU (20-fold) and HEU infants (7-fold). HEU infants also had a 3-fold higher incidence of IPD than HUU infants. When stratified into 2 age groups, incidence was similarly highest in HIV-infected infants, intermediate in HEU infants, and lowest in HUU infants (Table 1) . By 2013, although IRs had decreased due to PCV and HIV interventions, in all groups compared with 2009, relative trends in incidence by HIV exposure/infection status were similar. In 2013, among infants aged 6 to <12 months, incidence was similar between HEU and HUU cases, but case numbers were small in this age group, limiting the ability to detect relative differences in rates. Incidence rate and IRR were higher in the <6-month age group than in the 6-to <12-month age group regardless of HIV status (Table 1) .
Factors Associated With HIV Exposure and Infection Status
For cases <1 year of age, with known outcomes and HIV status, the overall case-fatality ratio was high (29% Table 1 ) were more likely to be >6 months of age, to be infected with penicillin-nonsusceptible S. pneumoniae, to have used cotrimoxazole prophylaxis in the last month, and to have died compared with HEU children. In addition, HIV-infected infants were less likely to have underlying conditions other than HIV and malnutrition.
When we restricted the analysis to cases <6 months of age (Table 2) , on multivariable analysis, HUU cases were at significantly lower risk of dying during the IPD episode, had a decreased risk of IPD caused by a penicillin-nonsusceptible strain, and had an increased risk of meningitis compared with pneumonia compared with HEU children with IPD. HIVinfected infants with IPD were more likely to have disease caused by a penicillin-nonsusceptible strain and be malnourished than HEU infants with IPD.
For cases aged 6 to <12 months (Table 3) , on multivariable analysis, HUU infants were less likely to be of black race and at significantly increased risk of dying from their IPD episode compared with HEU children. HIV-infected infants were more likely to be malnourished and die than HEU infants, despite having less-severe disease at time of presentation (as assessed with Pitt bacteremia score), and fewer underlying conditions other than HIV. Among HUU cases, underlying conditions were significantly more common in infants aged 6 to <12 months (41/141 [29.1%]) than in younger infants (22/ 209 [10.5%] (P < .001).
Factors Associated With Case Fatality
On multivariable analysis to explore factors associated with death, in infants aged <6 months (Table 4) , being of black race, malnourished, or HEU or HIV-infected and having meningitis (compared with pneumonia) were associated with an increased odds of death. In infants aged 6 to <12 months (Table 5) with malnutrition (compared with no malnutrition), those with meningitis (compared with pneumonia) and HUU cases (compared with HEU cases) had increased odds of death.
DISCUSSION
In South Africa, HIV-infected pediatric numbers continue to decline due to PMTCT improvements [1] ; however, numbers of HEU children remain high and are growing. We have shown that these HEU children are twice as likely to have an IPD-associated hospitalization; and that HEU children aged <6 months are less likely to survive an IPD episode than HUU children. It is important to prioritize and continue targeting these HEU children for public health interventions such as PCV vaccination.
Following PCV introduction into the national immunization program in South Africa, a significant reduction in vaccinetype disease in both HIV-infected and HIV-uninfected children was observed [15] . In our study, we similarly observed a reduction in the estimated incidence of IPD in HEU children from 2009 to 2013. Although other interventions such as improvements in maternal immune status [12] may have contributed to this, it is likely that the bulk of this reduction resulted from the introduction of PCV [15] . A case-control study from South Africa showed that PCV, when given in the routine program, was highly effective in HEU children [16] . Despite generally lower prevaccination antibody levels, HEU children respond quantitatively as well as HUU infants to routine immunization program vaccinations such as tetanus, pertussis, Haemophilus influenzae type b, and hepatitis B [17] . In contrast, PCV functional assays have shown that HEU children require higher antibody concentrations for effectiveness against certain pneumococcal serotypes [18] .
In South Africa, antiretroviral therapy (ART) coverage in HIV-infected children increased from 2004, but by 2011, pediatric ART initiation rates still lagged behind that of adults. Nationally, the 2011-2012 coverage for children aged <18 months was reported as 54.4% with large variations between districts [14, 19] . In our study, HIV-infected children still had an elevated risk of IPD-associated hospitalization (15-fold) and IPDrelated death (2-fold), compared with unexposed children. Other studies have shown that following ART introduction, although overall incidence of IPD decreased in HIV-infected children [20] , the absolute risk of IPD remained approximately 20-fold greater in HIV-infected than HIV-uninfected children <2 years of age [21] . A case-control study from South Africa found that HIV exposure was associated with nearly 2 times greater odds of all serotype IPD, although the control group in this study was children hospitalized with a nonpneumonia diagnosis, a group also at increased likelihood of HIV exposure, and therefore this study likely underestimated the increased odds of IPD associated with HIV exposure [16] .
In our study, a number of differences were noted between HEU, HUU, and HIV-infected infants with IPD. Malnutrition Abbreviations: ARRR, adjusted relative risk ratio; CI, confidence interval; HEU, HIV exposed but uninfected; HIV, human immunodeficiency virus; HUU, HIV unexposed and uninfected; IPD, invasive pneumococcal disease; RRR, relative risk ratio. a Asplenia, including asplenia or sickle cell anemia; chronic illness, including chronic lung, renal, liver, or cardiac disease, and diabetes; other immunocompromising conditions (excluding HIV), including organ transplant, primary immunodeficiency, immunotherapy, and malignancy; and other risk factors, including head injury with possible cerebrospinal fluid leak, neurological disorders, burns, and chromosomal abnormalities. Excludes malnutrition. b Malnutrition was classified as weight-for-age z score <−2 (World Health Organization child growth standards 2009) and/or nutritional edema.
c Pitt bacteremia score calculated using temperature, hypotension, mechanical ventilation, cardiac arrest, and mental status. Severe disease defined as score of ≥4 points.
d Any antibiotics used in 2 months prior to admission.
e Penicillin nonsusceptible minimum inhibitory concentration ≥0.12 μg/mL.
was significantly more common in HIV-infected infants, but not in HEU compared with HUU infants. This concurs with a review of studies that showed an association between HIV infection and being stunted or underweight [22] ; no differences were observed in the early growth of HEU children and healthy controls [22] . Combined ART used for PMTCT has been shown to cause lower birth weight and length in some HEU infants, but this rapidly corrects over the first few months of life [23] .
Other differences between the 3 IPD case groups included clinical presentation, with HUU IPD cases more likely to present with meningitis than pneumonia. HIV-infected children are less likely to be diagnosed with meningitis than other types of IPD [24] , and children with meningitis have a higher mortality than children with pneumonia or bacteremia, especially if they are HIV infected [24] . Specimen-collection practices differed between different case groups, reflecting different clinical syndromes; HUU infants were less likely to have blood cultures taken than HEU and HIV-infected infants.
Racial differences, with HUU children being more likely to be of nonblack race, has been shown in other local studies [25] . Children of black race had a higher likelihood of dying with IPD, possibly reflecting poorer socioeconomic status and higher HIV infection rates. IPD in HIV-infected individuals is more often caused by antibiotic-resistant strains than IPD in HIV- uninfected individuals [26, 27] . Antimicrobial resistance is an important adverse consequence of cotrimoxazole prophylaxis [28] ; this correlated with what we found in our study. Cohort studies suggest that mortality among children born to HIV-infected mothers is higher than that among children born to HIV-uninfected mothers [29, 30] . A pooled mortality analysis, using African data, showed a 9 times higher mortality rate in HIV-infected than HIV-uninfected children. Children with a early positive PCR result (<4 weeks of age) were more likely to die, as were those with mothers who died or who had low CD4
+ cell counts at delivery [31] . In our study, we observed a higher IPD-associated case fatality rate in HEU infants compared with HUU infants in the <6-month age group. The increased fatality rate among HEU children may be due to immunological differences that resolve as these children age; thus, younger HEU children may be more vulnerable to adverse clinical outcomes [32] . Other studies have also shown a higher mortality in younger HEU children [8] . In the older infants (6 to <12 months), this relationship was reversed, with HUU infants less likely to survive IPD, but there were small numbers of infants in the comparison group of HEU infants aged 6 to <12 months (n = 78). By 6 months of age, the immunologic deficit associated with HIV exposure is reduced [8] , and effects of HIV exposure on adverse outcomes in this group are less marked. Last, increased case-fatality rates in older HUU infants with IPD may be due to a higher proportion of these infants having an underlying condition or, possibly, other factors leading to high mortality in HUU infants with IPD that we were not able to document. Children with underlying conditions have been extensively described to have a higher risk of IPD than healthy children [33] . HIV infection is an independent risk factor for IPD [34, 35] . This would account for the higher rate of underlying conditions in HEU and HUU infants with IPD, compared to HIV-infected infants with IPD. The difference in underlying condition rates between HEU and HUU cases was not statistically significant and no solid conclusions could be made regarding this comparison. A number of factors are thought to contribute to differences in case-fatality rates between HEU and HUU children. Most important are different immunological deficits documented in HEU children [36] [37] [38] [39] . Second, a clear trend has been shown between the degree of maternal immunosuppression and infant survival [40] . We did not collect details regarding maternal CD4 count or use of ART by the mother during pregnancy and could therefore not explore this association further, which was a limitation.
Our study had other limitations. As with most surveillance studies, only patients who had samples taken could be identified as an IPD case and included in the study. For the multinomial and mortality analyses, we only included IPD cases from enhanced sites with viable isolates. These enhanced-site cases were more likely to be diagnosed with positive blood cultures, which may limit the generalizability of our findings. Infection status of HEU children was decided by 1 negative PCR result in some infants, so it is possible there may have been some misclassification of HIV status. The majority of patients had PCR testing done within a month of admission and nurses were trained to request retesting in symptomatic children, which would have minimized HIV-infected children being included in the HEU group. Some data, such as cotrimoxazole prophylaxis, were ascertained on verbal report if not available in the medical records; therefore, underreporting is possible.
In conclusion, we have described a higher incidence of hospitalization for IPD in HEU children compared with HUU children, as well as a lower chance of surviving IPD in HEU children <6 months of age compared with those who are HUU. Although we did not collect maternal data, we propose that optimizing maternal immunological status for HIV-infected women during pregnancy may help to improve outcomes in HEU children. Although widespread PCV introduction has led to substantial reductions in IPD incidence in South Africa [15] , some differences were observed in vaccination rates between HIV exposure groups. It is important to ensure that all HEU children receive PCV, to reduce the risk of IPD and its negative health outcomes, including death.
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